Today, Vinnova announced that Antaros Medical is one of the companies that receives funding through the call Innovationsprojekt i företag, for the development of an imaging tool for better diagnostics and treatment of patients with chronic kidney disease (CKD).
Antaros Medical CEO Johannes Hulthe says: Antaros is already today working with pharma companies, supporting them in understanding kidney disease and drug effects on kidneys, as part of Antaros cardiorenal and metabolic focus. Our data look very promising, so it is great that we have received the funding from Vinnova, so we can take the next step in developing an imaging tool for improved diagnosis that, hopefully, should support better treatment for patients in the future.
CKD is caused by many heterogeneous diseases that alter the function and structure of the kidney in different ways. Today there is a great need for improved biomarkers for the diagnosis of kidney disease, understanding the cause and refining the classification of the disease to further improve worldwide. CKD is, therefore, regarded as a global health burden and it has high prevalence particularly in older populations (~11% of the total population and 23-36% in the >64y population).